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Summary In this manuscript we describe the first association in the literature between
Abiotrophia defectiva endocarditis and the hemophagocytic syndrome. There are multiple
important clinical points of information that must be highlighted from this case. A. defectiva
is an aggressive organismwith a high level of resistance to antibiotic pharmacotherapy with a high
predilection for embolic complications and valvular destruction despite treatment with sensitive
antibiotics. A. defectiva endocarditis has not been previously associated with the hemophago-
cytic syndrome. However, this case highlights the serious hematological complications that can
occur with this dangerous bacterial pathogen.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
Abiotrophia defectiva, a nutritionally variant streptococcus
(NVS), represents a rare but clinically important cause of
infective endocarditis. The hemophagocytic syndrome is a
destructive bone-marrow depleting condition that can be
primary or secondary in etiology. The early diagnosis is
essential to initiate the correct treatment and prevent
potentially fatal complications. This case highlights the
identification, clinical course, treatment, and sequelae of* Corresponding author. Tel.: +353 6175432799.
E-mail address: tom_kiernan@hotmail.com (T.J. Kiernan).
1201-9712/$32.00 # 2008 International Society for Infectious Diseases.
doi:10.1016/j.ijid.2008.01.014A. defectiva endocarditis and associated hemophagocytic
syndrome (HPS).
Case report
A 29-year-old male presented to an outside hospital with
vomiting, abdominal pain, and general malaise. A three-
month history of weight loss, night sweats, and fatigue,
preceded by a dental infection was elicited. Past medical
history was unremarkable. Physical examination revealed
pallor, finger clubbing, and an apical pansystolic murmur
of mild mitral regurgitation. Initial laboratory investiga-
tions revealed a neutrophilia and an elevated erythrocytePublished by Elsevier Ltd. All rights reserved.
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endocarditis, intravenous antibiotics were commenced and
included benzylpenicillin 2.4 g q4-hourly and gentamicin
1 mg/kg q8-hourly after three sets of blood cultures had
been taken. Transthoracic echocardiography revealed a small
mobile structure resembling a vegetation on the atrial side of
the posterior mitral valve leaflet and Doppler evidence of
mild mitral regurgitation.
The aerobic and anaerobic cultures of the first set of blood
cultures were positive at 20- and 22-h, respectively. Blood
cultures were incubated in a BacTALERT blood culture system
(BioMerieux UK Ltd). Gram staining revealed Gram-positive
cocci arranged in chains. Subsequent culture revealed an
alpha-hemolytic streptococcus initially thought to be a vir-
idans type streptococcus. Disk susceptibility testing by Clin-
ical and Laboratory Standards Institute (CLSI) method
indicated that the organism was susceptible to penicillin.
The organism was identified as A. defectiva by API Rapid ID 32
Strep (BioMe´rieux, Marcy l’Etoile, France). This was con-
firmed by the Colindale Reference Laboratory, London, UK;
the penicillin minimum inhibitory concentration (MIC) was
reported as 0.50 mg/l. Antibiotic therapy continued to
include benzylpenicillin 2.4 g q4-hourly and gentamicin
1 mg/kg q8-hourly, according to the guidelines of the Amer-
ican Heart Association for the treatment of A. defectiva
endocarditis (penicillin MIC 0.5 mg/l). The patient had a
prompt clinical response to antibiotic therapy, with a fall in
serumwhite cell count (WCC) and inflammatory markers over
the following two weeks.
On day 19 the patient became pyrexial with a temperature
of 40 8C. The patient was tachycardic with a resting heart
rate of 120 beats per minute and hypotensive with a blood
pressure of 90/50 mmHg. Physical findings included a macu-
lopapular rash on the abdomen, splenomegaly, and worsening
of mitral regurgitation. Inflammatory markers also increased
at this stage in conjunction with a new thrombocytopenia and
elevated D-dimers. Urgent transesophageal echocardiogra-
phy revealed a vegetation on the anterior mitral valve leaflet
with significant destruction of the posterior mitral valve
leaflet and moderate to severe mitral regurgitation. The
onset of these new signs despite adequate antimicrobial
therapy prompted immediate surgical intervention.
The patient bled excessively with the loss of 2 l of blood
during mitral valve replacement surgery. Continued blood
loss of greater than 200 ml/h occurred in the postoperative
period despite administration of packed red cells, solvent
detergent plasma, platelets, cryoprecipitate, and recombi-
nant VIIa (Novoseven1). There was evidence of hyperfibri-
nolysis with a D-dimer level of greater than 10 000 ng/ml and
a Clauss fibrinogen of less than 1.5 g/l despite replacement
therapy. The patient subsequently became increasingly pan-
cytopenic with a nadir WCC of less than 1  109/l and a
platelet count of 14  109/l. Inflammatory markers were
persistently raised. His triglycerides were elevated at
4.7 mmol/l and his ferritin was modestly elevated. A bone
marrow aspirate performed at this stage showed a marked
reduction in all three cell lines with numerous activated
histiocytes and evidence of hemophagocytosis.
In light of the progressive pancytopenia, raised triglycer-
ides, hyperfibrinolysis, and clinical features of skin rash and
splenomegaly, a diagnosis of hemophagocytic lymphohistio-
cytosis was made and the patient was commenced onmethyl-prednisolone at a dose of 1 mg/kg for three weeks in total. He
also received intravenous immunoglobulin and a short course
of granulocyte-colony stimulating factor. The response to
treatment was dramatic with resolution of bleeding and
transfusion independence within 48 h of commencing steroid
therapy. The patient received 60 units of packed red cells, 40
units of solvent detergent plasma, 20 units of platelets, 150
units of cryoprecipitate, and eight treatment doses of recom-
binant VIIa (Novoseven) in the 10 days postoperatively. Full
blood count and coagulation screen remained normal after
discontinuation of methylprednisolone but his hospital stay
was complicated by a sternal wound infection. He was even-
tually discharged home on day 111. Subsequent testing has
ruled out an underlying bleeding disorder. His triglycerides,
ferritin, and inflammatory markers have normalized and he is
clinically well despite his stormy clinical course.Abiotrophia defectiva endocarditis
Microbiology and pathology
NVS were initially described by Frenkel and Hirsch in 1961 as
fastidious Gram-positive bacteria that exhibited satellitism
around other bacteria.1 The nomenclature of these bacteria
changed repeatedly in the following years. In 1989, Bouvet
et al. proposed the names Streptococcus defectivus and
Streptococcus adjacens, following the use of DNA—DNA hybri-
dization studies, which revealed NVS were taxonomically
distinct from the other viridans group organisms, to which
they were originally thought to be related.2 In 1995, Kawa-
mura and associates used 16S RNA (rRNA) sequence analysis
on these two species. Analysis showed that the species were
not related to the Streptococcus genus. They proposed pla-
cing these organisms in a new genus Abiotrophia, to be
named as A. adjacens and A. defectiva, respectively.3 In
2000, Collins and Lawson proposed the re-classification of
all Abiotrophia species except A. defectiva into the new
genus Granulicatella, based on the 16S rRNA heterogeneity
and phenotypic differences observed.4
Accurate identification of NVS can be difficult due to the
pleomorphic nature and variable Gram-staining characteris-
tics of the organism.5 The cells are Gram-positive, mainly
cocci, but pleomorphic ovoid cells, coccobacilli, and rod-
shaped cells may also occur. Extended incubation may be
required for NVS to grow. For subculture, solid media must be
supplemented with pyridoxal or L-cysteine to sustain
growth.2 Kanamoto et al. investigated A. defectiva, Granu-
licatella adiacens, and Granulicatella elegans amongst other
strains from endocarditis patients. Useful phenotypic char-
acteristics that can be used to differentiate between species
within the Abiotrophia and Granulicatella genera are pro-
duction of alpha- and beta-galactosidase (A. defectiva),
beta-glucuronidase (G. adiacens), and hydrolysis of hippu-
rate (G. elegans).6
Molecular techniques such as 16S ribosomal RNA gene
sequencing using polymerase chain reaction—restriction
fragment length polymorphism (PCR—RFLP) analysis may
be necessary to identify A. defectiva as the causative organ-
ism where blood cultures are negative.7 It should be stated
that while the use of molecular techniques in the diagnosis
of culture-negative endocarditis is extremely helpful, the
480 T.J. Kiernan et al.sensitivity of the technique is much greater in resected
valves than in blood.8
Clinical course
A. defectiva is primarily isolated from the oral cavity but can
also be found in the intestinal and genito-urinary tracts.9
Rates of oral colonization of A. defectiva in healthy indivi-
duals has been reported at a level of 11.8%.10 Through these
portals, entry is gained to the bloodstream. A. defectiva has
also been implicated in causing osteomyelitis,11 cerebral
abscess,12 septic arthritis,13 and meningitis.14 NVS are said
to cause 5% of all cases of bacterial endocarditis.17 A.
defectiva endocarditis is therefore a rare cause of endocar-
ditis; it is said to cause 5% of all cases of streptococcal
endocarditis.16 There are approximately 100 cases of A.
defectiva endocarditis in the literature.16,17 Endocarditis
caused by A. defectiva predominantly occurs in the setting
of preexisting heart disease (90%); prosthetic heart valves
are involved in 10% of patients.18 While there are case reports
in the literature of children without previous valvular heart
disease developing A. defectiva endocarditis,19,20 there are
no published cases on adults without previously documented
valvular heart disease developing A. defectiva endocarditis.
Endocarditis caused by NVS carries greater morbidity and
mortality than endocarditis caused by streptococci.21
In the majority of cases, the clinical course is slow and
indolent. Often there is a history of dental manipulation in
the preceding months or a history of dental caries, as this is
the predominant route of entry of the organism into the
bloodstream. Despite forming relatively small vegetations,
embolization occurs in up to one-third of patients.18 Con-
gestive cardiac failure and the need for surgical intervention
is higher with endocarditis due to NVS versus other strepto-
cocci.21 The aortic andmitral valves are affected with similar
frequency, 13% and 11%, respectively. Mortality data are
based on the former nomenclature of NVS and denote that
mortality is indeed higher (17%) when compared to endocar-
ditis caused by viridans streptococci (0—12%) or by entero-
cocci (9%).22 The majority of deaths are due to refractory
congestive cardiac failure ormajor systemic emboli. Approxi-
mately 27% of patients require prosthetic valve replacement.
Treatment
A. defectiva endocarditis is difficult to treat and has a
bacteriologic failure rate of 41% despite therapy with anti-Table 1 The American Heart Association guidelines for treatmen
Antimicrobial regimen Dose and route
Ampicillin 12 g/24 h, 6 divided doses IV
Or penicillin 18—30 million units/24 h, 6 divided dose
Plus gentamicin 3 mg/kg/24 h, 3 divided doses
Vancomycin 30 mg/kg/24 h, 2 divided doses
Plus gentamicin 3 mg/kg/24 h, 3 divided dosesbiotics that are effective in vitro. It has also been shown that
the relapse rate can be up to 17% in certain cases.18 Studies
have shown that resistance among A. defectiva species to
beta-lactam and macrolide antibiotics has increased,23 with
one study demonstrating that only 8% of A. defectiva exhib-
ited susceptibility to penicillin.24 Even with strains highly
susceptible to penicillin, relapse may still occur after the
appropriate course of therapy, as demonstrated in this case
report. Using animal models of endocarditis it has been
shown that the combination of penicillin and gentamicin is
more effective than penicillin alone.25 Vancomycin repre-
sents a good therapeutic choice in patients who have shown a
poor response to penicillin—aminoglycoside combination
therapy.18
The American Heart Association guidelines suggest treat-
ment of endocarditis due to NVS is dictated by the penicillin
MIC and should follow the guidelines for the treatment of
enterococcal endocarditis. This includes a regimen of peni-
cillin or ampicillin plus an aminoglycoside for four to six
weeks as shown in Table 1.26 In this case, the patient received
benzylpenicillin 2.4 g q6-hourly for 6 weeks and gentamicin
1 mg/kg q8-hourly for 4 weeks post-valve replacement.
Repeat blood cultures were sterile.
The reasons for high antibiotic treatment failure rates are
multiple in nature. First of all, a longer time period is
required for identification and isolation of these bacteria
due to their slow and fastidious growth characteristics; blood
cultures can take at least 2—3 days to become positive and
then usually subculture with L-cysteine-supplemented media
is required. They produce large amounts of exopolysacchar-
ide in vivo, further adding to their virulence. The increased
resistance and tolerance to penicillin, the mainstay of treat-
ment, have also contributed to the difficulties in treatment
of A. defectiva endocarditis.
Hemophagocytic syndrome
HPS is a disorder characterized by fevers, lymphadenopathy,
hepatosplenomegaly, maculopapular rash, cytopenias, and
hyperferritinemia due to dysregulated activation and prolif-
eration of macrophages, leading to uncontrolled phagocyto-
sis of platelets, erythrocytes, lymphocytes, and their
hematopoietic precursors throughout the reticuloendothelial
system. Primary or familial HPS appears to have a genetic
etiology, whereas secondary HPS may be associated with
malignancy, autoimmune disease, or infection. Epstein—Barr
virus is the most common infectious etiology implicated int of endocarditis due to nutritionally variant streptococcus
Duration (weeks) Comment
4 4 weeks if symptoms for >3 months
(native valve) 6 weeks if symptoms
<3 months/prosthetic valve
s
4—6 Provided renal function normal
6 Alternative for penicillin-allergic
patient provided renal function
normal
6
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other viral, bacterial, and parasitic pathogens, including HIV,
cytomegalovirus, Salmonella typhi, Histoplasma capsula-
tum, Leishmania species, and Toxoplasma gondii.28
The pathophysiological basis for HPS remains poorly
understood. In patients with HPS, splenic macrophages
appear to be activated, as evidenced by increased expression
of major histocompatibility complex (MHC)-I and MHC-II
molecules.29 In addition, patients with active HPS have sub-
stantially raised serum levels of the proinflammatory cyto-
kines interferon-g,30 interleukin-12,31 interleukin-18,32,33
tumor necrosis factor-a,31 interleukin-1b,34 and interleu-
kin-6,30 compared with controls.
In addition to increased destruction of hematopoietic
cells by uncontrolled phagocytosis, concomitant depression
of granulocyte and erythroid precursors may be observed in
the bone marrow, likely due to the secretion of inhibitory
cytokines.35,36 Inadequate cellular cytotoxicity due to
improper intracellular trafficking, impaired apoptosis, and
defects in effectormolecules such as perforin have also been
implicated.37,38 Patients with secondary HPS may develop
severe quantitative and functional deficiencies of natural
killer (NK) cells during the course of their illness.39,33 A
subsequent disordered and inadequately regulated immune
response may result in survival and proliferation of the
organism, resulting in ongoing immunological stimulation.
Increased expression of proinflammatory cytokines by acti-
vated T cells may then lead to uncontrolled macrophage
activation. The end result is an ineffectual and destructive
immunological response that escapes the usual mechanisms
of autoregulation.
Treatment
The aim in the treatment of any patient with acquired HPS is
to suppress the severe hyperinflammation that is responsible
for the life-threatening symptoms. Another aim is to kill
pathogen-infected antigen-presenting cells and thus remove
the stimulus for the ongoing but ineffective activation of T
cells. It has to be specifically emphasized that pathogen-
directed therapy is usually not sufficient to control hyperin-
flammation.
Hyperinflammation can be treated with corticosteroids,
which are cytotoxic for lymphocytes and inhibit expression of
cytokines and differentiation of dendritic cells. Since dex-
amethasone crosses the blood—brain barrier better than
prednisolone it is the preferred corticosteroid. Cyclosporin
prevents T-lymphocyte activation and immunoglobulin infu-
sions probably by providing cytokine- and pathogen-specific
antibodies. In patients with less severe symptoms, corticos-
teroids and immunoglobulin infusions are sometimes suffi-
cient to control hyperinflammation and to reverse the clinical
and laboratory symptoms.
Conclusions
Our case as discussed above is the first association in the
literature between Abiotrophia defectiva endocarditis and
the hemophagocytic syndrome. There are multiple important
clinical points of information that must be highlighted from
this case.1. defectiva is an aggressive organism that can demonstrate
resistance and tolerance to antibiotic pharmacotherapy.
This case highlights the unpredictable nature of A. defec-
tiva endocarditis infection, its potential for late compli-
cations, antibiotic failure, and possibly an immune
response initiating devastating complications.2. defectiva endocarditis predisposes to embolic complica-
tions and valvular destruction despite treatment with
sensitive antibiotics. The clinical course of the patient
with endocarditis is always monitored in a very intensive
and thorough manner, but our guard needs to be even
higher with A. defectiva endocarditis.3. defectiva endocarditis has not been previously associated
with the hemophagocytic syndrome. This case highlights
the serious hematological complications that can occur
with this dangerous bacterial pathogen.Conflict of interest: No conflict of interest to declare.
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